Pregnancy check-in program after TEGSEDI exposure
Part of Genetic & congenital, Women’s health & pregnancy clinical trials.
This study follows pregnant people who either took TEGSEDI or did not take it, to better understand pregnancy outcomes in transthyretin amyloid polyneuropathy (hATTR-PN). Your participation may help doctors guide safer pregnancy care for people with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant now or were pregnant recently and are part of the study as a TEGSEDI exposure case or a non-exposure case
- If you took TEGSEDI: you took at least 1 dose within 25 weeks before conception or during pregnancy
- If you did not take TEGSEDI: you have a diagnosis of hATTR-PN during pregnancy
- You have not taken TEGSEDI within 25 weeks before conception or during pregnancy (for the non-exposed group)
- You are able and willing to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people after they had a NIPT blood test during pregnancy to better understand outcomes. If you were tested through Sequenom/Integrated Genetics and your pregnancy outcome is known, you may be eligible.
This program tracks pregnancy outcomes for people who were exposed to patisiran (a medicine) in a special delivery form called LNP during pregnancy or shortly before. It helps doctors understand potential effects and safety for mothers and babies.
This trial tests whether the drug tafamidis can help people with a specific type of nerve damage caused by abnormal protein buildup. It aims to slow or improve symptoms in adults with this condition.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
This trial is for people with a specific inherited form of amyloidosis caused by a change in the TTR gene. It offers a comprehensive care program to help manage this rare condition.
This study follows pregnant people who took tildrakizumab to understand pregnancy outcomes and safety. It also compares them with pregnant people with the same underlying disease who did not take tildrakizumab during this pregnancy.
Hear when a new Pregnancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.